SCHEMBL30296607

SCHEMBL30296607

Nc1cc(Cl)c(-c2ccc(OC3CCCC3)nc2)cc1F

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TDO2 P48775 3/20 0.43
PAICS P22234 2/20 0.39
ALOX5AP P20292 4/20 0.39
FEN1 P39748 4/20 0.39
DGAT1 O75907 3/20 0.38
EGFR P00533 1/20 0.36
ITK Q08881 1/20 0.36
FAAH O00519 1/20 0.36
KCNH2 Q12809 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
PIM1 P11309 1/20 0.36
PIM3 Q86V86 1/20 0.36
PIM2 Q9P1W9 1/20 0.36
SCN9A Q15858 3/20 0.36
SCN5A Q14524 1/20 0.36
FFAR1 O14842 1/20 0.36
FFAR4 Q5NUL3 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26461154 1.00 TDO2 (0.43) TDO2PAICSALOX5APFEN1DGAT1
SCHEMBL30296462 0.98 TDO2 (0.43) TDO2PAICSALOX5APFEN1DGAT1
SCHEMBL30296663 0.95 TDO2 (0.45) TDO2PAICSALOX5APFEN1DGAT1
SCHEMBL30296565 0.90 TDO2 (0.41) TDO2PAICSALOX5APFEN1DGAT1
SCHEMBL31207378 0.90 ALOX5AP (0.45) TDO2PAICSALOX5APFEN1DGAT1
SCHEMBL31207445 0.88 FEN1 (0.45) TDO2PAICSALOX5APFEN1DGAT1
SCHEMBL30296242 0.87 TDO2 (0.38) TDO2PAICSALOX5APFEN1DGAT1
SCHEMBL30296497 0.87 TDO2 (0.38) TDO2PAICSALOX5APFEN1DGAT1
SCHEMBL26459805 0.87 TDO2 (0.38) TDO2PAICSALOX5APFEN1DGAT1
SCHEMBL26459487 0.87 TDO2 (0.38) TDO2PAICSALOX5APFEN1DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4702021-A1 COMPOUNDS CAPABLE OF MODULATING GPR65 Pathios Therapeutics Limited (GB) 2026-03-04 EP disclosed
US-20240368173-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2024-11-07 US disclosed
WO-2024224064-A1 COMPOUNDS CAPABLE OF MODULATING GPR65 Pathios Therapeutics Limited (GB) 2024-10-31 WO disclosed
EP-4419203-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2024-08-28 EP disclosed
CN-118451080-A Tricyclic GPR65 modulators 帕蒂奥斯治疗有限公司 2024-08-06 CN disclosed
WO-2023067322-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2023-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368173-A1 TRICYCLIC GPR65 MODULATORS GPR65, GPR3, NR1H2 TDO2 2047/4885PAICS 4249/4885ALOX5AP 1484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.